The financing was co-led by Forbion and Corteva to accelerate the commercial rollout of disease-resistant banana varieties.
"This funding is a powerful endorsement of our team’s ability to bring breakthrough products to the hands of growers, exporters and consumers around the world. We are entering a new era, one where gene‑edited crops will significantly enhance food security and sustainability. 2025 proved that our technology delivers – not in the distant future, but right now. With two banana varieties already on the market and demand outstripping supply, this investment enables us to scale global production and expand into new crops faster than ever before. We are excited to be partnering with our new investors as we progress our mission to build a world-leading tropical seeds company."
The Series A financing was led by Forbion and HV Capital to fund a new pilot production line.
"The founders' mission is to combine scientific innovation with design excellence to create beautiful, environmentally friendly materials that meet the exacting standards of global luxury brands while enabling broad industry adoption."
The financing round was co-led by RA Capital Management and Forbion to support late-stage clinical development.
"We are delighted to secure the investment required to continue to advance inobrodib fully and as effectively as possible. This is a significant raise in a challenging market. Today's announcement is a testament to the data we have in hand, the clear clinical and commercial opportunity inobrodib represents, and the strength of our expanded team."
The Series A round was co-led by Forbion and General Atlantic to support clinical trials and portfolio expansion.
"People living with obesity and its complications deserve better options at each stage of their treatment journey. These include oral therapies with less frequent dosing regimens, which have the potential for improved efficacy and tolerability, and innovative combination therapies for healthier weight loss and—equally importantly—maintenance of metabolically healthy weight. We created Verdiva Bio to accelerate the development of differentiated medicines that address these significant unmet medical needs."
The financing round was led by Sofinnova Partners and will fund upcoming clinical trials for kidney disease treatments.
"Our investment into Purespring Therapeutics fits perfectly into our strategy to support the UK’s life sciences and is the type of UK growth company which could benefit further by unlocking the potential of institutional investment. We need to support companies like Purespring as they go through development and trials before coming to market.Providing that capital simultaneously stimulates growth and helps to solve pressing medical challenges that will deliver long-term outcomes for generations to come."
— Ian Connatty, Managing Director, Direct & Co-Investment
